================================================================================
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 22, 2009
ONCOLOGIX TECH, INC.
---------------------------------------------------------
(Name of Small Business Issuer as Specified in Its Charter)
0-15482
----------------------
(Commission File Number)
Nevada 86-1006416
------------------------------ -----------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
P.O. Box 8832
Grand Rapids, MI 49518-8832
--------------------------------------
(Address of principal executive offices)
(616) 977-9933
-------------------------
(Issuer's telephone number)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
================================================================================
EXPLANATORY NOTE
This amendment to the Current Report on Form 8-K filed by Oncologix Tech, Inc.
(the "Company") with the Securities and Exchange Commission on August 13, 2009
is filed solely to correct two clerical errors: 1) The original filing was
tagged incorrectly under Item 9.01 instead of Item 4.01 and 2) the independent
accountant's letter was incorrectly filed as Exhibit 99 instead of Exhibit 16.
Item 4.01 - Changes in Registrant's Certifying Accountant
a)
1) On June 19, 2009, the Board of Directors of the Registrant
recommended and approved the dismissal of Semple, Marchal &
Cooper, LLP as the Registrant's independent registered public
accounting firm effective June 19, 2009.
2) The reports of Semple, Marchal & Cooper, LLP on the Registrant's
consolidated financial statements for the fiscal years ended
August 31, 2007 and 2006 did not contain any adverse opinion or
disclaimer of opinion and were not qualified or modified as to
audit scope or accounting principles. Their opinion was qualified
due to uncertainty as to the Registrant's ability to continue as
a going concern.
3) The decision to change the Registrant's independent registered
public accounting firm was recommended and approved by the
Registrant's Board of Directors.
4) During the fiscal years ended August 31, 2007 and 2006, as well
as the nine-month period ended May 31, 2008 and through the date
of this Form 8-K, there were no disagreements between the
Registrant and Semple, Marchal & Cooper, LLP on any matter of
accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreements,
if not resolved to the satisfaction of Semple, Marchal & Cooper,
LLP, would have caused Semple, Marchal & Cooper, LLP to make
reference to the subject matter of the disagreements in
connections with its report.
The Registrant has requested Semple, Marchal & Cooper, LLP to furnish the
Registrant with a letter addressed to the SEC stating whether Semple, Marchal &
Cooper, LLP agrees with the above statements. A copy of Semple, Marchal &
Cooper, LLP's letter, dated June 22, 2009, is attached as exhibit 99 to this
Form 8-K.
b) On June 22, 2009, the Board of Directors of the Registrant recommended
and approved the appointment of Chisholm, Bierwolf, Nilson & Morrill,
LLC. as the Registrant's independent registered public accounting
firm, effective June 19, 2009.
During the fiscal years ended August 31, 2007 and 2006 as well as the
nine-month period ended May 31, 2008 and through the date of this Form 8-K,
neither the Registrant nor anyone acting on its behalf consulted Chisholm,
Bierwolf, Nilson & Morrill, LLC. regarding: (A) either the application of
accounting principles to a specified transaction, either completed or proposed,
or the type of audit opinion that might be rendered on the Registrant's
consolidated financial statements; or (B) any matter that was either the subject
of a disagreement with Semple, Marchal & Cooper, LLP on accounting principles or
practices, financial statement disclosure, or auditing scope or procedure which,
if not resolved to the satisfaction of Semple, Marchal & Cooper, LLP, would have
caused Semple, Marchal & Cooper, LLP to make reference to the matter in
connection with its report, or a "reportable event" as described in Item
304(a)(1)(v) of Regulation S-K of the SEC.
Item 9.01 - Exhibits
16 Letter to the Securities and Exchange Commission from Semple,
Marchal & Cooper, LLP dated June 22, 2009.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Dated: August 13, 2009 ONCOLOGIX TECH, INC.
By: /s/ Anthony Silverman
--------------------------------
Anthony Silverman,
Chief Executive Officer
and President
By: /s/ Michael A. Kramarz
--------------------------------
Michael A. Kramarz,
Chief Financial Officer